Invitrogen Closes $210M Sale of BioReliance to Avista Capital | GenomeWeb

Invitrogen Closes $210M Sale of BioReliance to Avista Capital

Apr 13, 2007

NEW YORK (GenomeWeb News) - Invitrogen has closed the $210 million sale of its BioReliance unit to Avista Capital Partners as part of its plans to better organize some of its acquisitions and streamline its focus, the company said today.

As GenomeWeb Daily News reported on Feb. 14, Invitrogen’s CEO and chairman Greg Lucier agreed to sell the biological services unit to Avista in an effort to focus on its platform of scientific technologies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

In on the Action

NPR reports that with medical data being big business, some companies want to get patients involved.

What's in Store?

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

This Week in PNAS

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Warren Releases Genetic Ancestry Results

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.